```html

Zollinger‑Ellison Syndrome (Gastrinoma): A Comprehensive Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas, duodenum, or nearby lymph nodes. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.

• Incidence: Approximately 0.5–2 cases per million people per year.<sup>1</sup>
• Age: Most commonly diagnosed between ages 30–60, but can occur at any age.
• Sex: Slight male predominance (≈55 % male).
• Associated condition: About 20‑30 % of patients have Multiple Endocrine Neoplasia type 1 (MEN‑1), an inherited syndrome that predisposes to tumors of the parathyroid, pituitary, and pancreas.<sup>2</sup>

Symptoms

Symptoms result from excess gastric acid and from the tumor’s local effects. They may develop gradually or present abruptly.

Gastro‑intestinal symptoms

• Refractory peptic ulcer disease – ulcers in unusual locations (duodenum beyond the first part, jejunum, or even the esophagus) that do not heal with standard therapy.
• Abdominal pain – burning or gnawing pain, often worse after meals.
• Chronic diarrhea – watery, sometimes fatty (steatorrhea) due to acid‑induced damage to the intestinal mucosa.
• Nausea & vomiting – especially after large meals.
• Weight loss – from malabsorption and reduced appetite.

Systemic symptoms

• Fatigue – secondary to anemia, electrolyte loss, or malnutrition.
• Gastro‑esophageal reflux disease (GERD) – heartburn caused by high gastric acid spilling into the esophagus.
• Signs of MEN‑1 (if present) – hyperparathyroidism (high calcium), pituitary tumors (headaches, vision changes).

Rare or late‑stage symptoms

• Obstructive jaundice (if tumor compresses the bile duct).
• Gastrointestinal bleeding – melena or hematemesis.
• Intestinal obstruction from large tumors.

Causes and Risk Factors

ZES is caused by gastrin‑producing neuroendocrine tumors. The exact trigger for sporadic gastrinomas is unknown, but several risk factors are recognized.

Genetic factors

• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an autosomal‑dominant mutation in the MEN1 gene, present in ~25 % of ZES cases.<sup>2</sup>
• Familial gastrinoma syndromes – rare inherited patterns not linked to MEN‑1.

Environmental / lifestyle factors

• No strong links to diet, smoking, or alcohol have been established, unlike many other peptic ulcer diseases.

Other risk considerations

• Age and sex – slight male predominance and peak incidence in middle adulthood.
• Previous gastric surgery – may mask symptoms, delaying diagnosis.

Diagnosis

A systematic approach is needed to confirm excess gastrin production, locate the tumor, and rule out other causes of high acid.

Initial laboratory evaluation

• Fasting serum gastrin level – levels >1000 pg/mL (normal <100 pg/mL) are strongly suggestive, especially when accompanied by low gastric pH (<2).<sup>3</sup>
• Secretin stimulation test – in ZES, gastrin paradoxically rises >120 pg/mL after intravenous secretin, whereas most other conditions show a decrease.
• Gastric pH measurement – a pH <2 confirms hyperacidity.
• Other labs – CBC, electrolytes, calcium, and parathyroid hormone to assess MEN‑1 involvement.

Imaging studies to locate gastrinomas

1. Endoscopic ultrasound (EUS) – high‑resolution view of the pancreas and duodenum; sensitivity up to 80 % for small lesions.
2. Multiphasic contrast‑enhanced CT scan – identifies tumors >1 cm and assesses metastasis.
3. Magnetic resonance imaging (MRI) with secretin stimulation – especially useful for liver metastases.
4. Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – detects neuroendocrine tumors that express somatostatin receptors, improving detection of occult lesions.

Histopathology (when surgery is performed)

If a tumor is removed, pathology confirms a well‑differentiated neuroendocrine tumor (NET) with immunohistochemical staining for gastrin, chromogranin A, and synaptophysin.

Diagnostic criteria summary

• Elevated fasting gastrin >1000 pg/mL or gastrin >200 pg/mL with secretin‑stimulated rise.
• Documented gastric acid hypersecretion (pH <2).
• Imaging documentation of a gastrin‑producing tumor.

Treatment Options

Therapy aims to control acid hypersecretion, eradicate or control tumor growth, and manage complications.

Acid‑suppression (first‑line)

• Proton pump inhibitors (PPIs) – e.g., omeprazole 40–80 mg daily or higher divided doses. PPIs are the most effective agents, often requiring >2× the usual ulcer dose.<sup>4</sup>
• Histamine‑2 receptor antagonists (H2 blockers) – may be added for breakthrough symptoms, but PPIs are preferred.

Surgical management

1. Curative resection – indicated when the tumor is localized (<2 cm) and there is no metastatic disease. Options include enucleation or pancreaticoduodenectomy (Whipple procedure) based on location.
2. Debulking surgery – for unresectable or metastatic disease to reduce tumor burden and improve symptom control.

Medical therapies for tumor control

• Somatostatin analogues (octreotide or lanreotide) – bind somatostatin receptors, inhibiting gastrin release and may shrink tumors. Useful in metastatic or MEN‑1‑related disease.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, well‑differentiated pancreatic NETs.
• Chemotherapy – reserved for high‑grade or poorly differentiated neuroendocrine carcinomas (e.g., streptozocin + 5‑FU or temozolomide‑based regimens).
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for tumors with high somatostatin‑receptor expression; shown to improve progression‑free survival.

Liver metastasis management

• Radiofrequency ablation, trans‑arterial embolization, or surgical resection when feasible.
• Systemic therapies (as above) if widespread.

Lifestyle and supportive measures

• Small, frequent meals low in fat and acid–triggering foods.
• Avoid NSAIDs, aspirin, and alcohol, which worsen ulcer disease.
• Supplementation with calcium, vitamin D, and iron if malabsorption is present.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Long‑term management involves adherence to medication, monitoring, and lifestyle adjustments.

Medication adherence

• Take PPIs exactly as prescribed – usually before breakfast and dinner.
• Set reminders or use a pill‑box to avoid missed doses.
• Report any breakthrough heartburn or ulcer pain to your clinician promptly.

Regular follow‑up

• Clinic visits every 3–6 months for symptom review, gastrin level check, and imaging as indicated.
• Annual endoscopy to assess ulcer healing and screen for new lesions.
• If you have MEN‑1, coordinate care with an endocrinologist for screening of parathyroid and pituitary disease.

Dietary tips

• Eat low‑acid foods (bananas, oatmeal, rice, lean proteins).
• Limit citrus, tomato‑based sauces, coffee, and carbonated drinks.
• Stay hydrated – water helps dilute gastric acid.
• Consider a dietitian referral for individualized nutrition plans, especially if weight loss or malabsorption is an issue.

Managing diarrhea

• Keep a stool diary to identify triggers.
• Pancreatic enzyme supplements may help if fat malabsorption is documented.
• Probiotic formulations (e.g., Lactobacillus rhamnosus) can improve gut flora and consistency.

Psychosocial support

Living with a chronic, rare condition can be stressful. Support groups, counseling, and patient advocacy organizations (e.g., Neuroendocrine Tumor Research Foundation) are valuable resources.

Prevention

Because most gastrinomas are sporadic and the exact cause is unknown, primary prevention is limited. However, you can reduce complications and possibly delay tumor detection:

• Screen high‑risk individuals – family members of MEN‑1 patients should undergo genetic counseling and periodic gastrin level checks.
• Avoid chronic ulcer‑causing agents – limit long‑term NSAID or aspirin use without protection.
• Promptly treat H. pylori infection – while unrelated to ZES, eradication reduces background ulcer risk.
• Maintain regular medical care – early evaluation of persistent ulcer symptoms leads to quicker diagnosis.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory peptic ulcer disease – perforation or bleeding requiring emergency surgery.
• Gastro‑intestinal bleeding – melena, hematemesis, anemia.
• Malabsorption and nutrient deficiencies – especially iron, calcium, and fat‑soluble vitamins (A, D, E, K).
• Kidney stones – hypercalciuria secondary to chronic acid load.
• Osteoporosis – chronic calcium loss.
• Metastatic disease – about 60 % of gastrinomas develop liver metastases over time.
• MEN‑1 associated complications – hyperparathyroidism, pituitary adenomas, and other endocrine tumors.

When to Seek Emergency Care

---

Sources:
1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” Accessed 2024.
2. NCCN Guidelines for Neuroendocrine and Adrenal Tumors, Version 2.2024.
3. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023.
4. Kushner, J. et al. “High-dose proton pump inhibitor therapy in Zollinger‑Ellison syndrome.” *Gastroenterology*, 2022.
5. WHO Classification of Tumours of Endocrine Organs, 5th edition, 2022. ```